Cargando…

A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer

PURPOSE: The study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer. METHODS: Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-can...

Descripción completa

Detalles Bibliográficos
Autores principales: Bi, Zhao, Qiu, Peng-Fei, Zhang, Yue, Song, Xing-Guo, Chen, Peng, Xie, Li, Wang, Yong-Sheng, Song, Xian-Rang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685269/
https://www.ncbi.nlm.nih.gov/pubmed/34938660
http://dx.doi.org/10.3389/fonc.2021.779140
_version_ 1784617798036619264
author Bi, Zhao
Qiu, Peng-Fei
Zhang, Yue
Song, Xing-Guo
Chen, Peng
Xie, Li
Wang, Yong-Sheng
Song, Xian-Rang
author_facet Bi, Zhao
Qiu, Peng-Fei
Zhang, Yue
Song, Xing-Guo
Chen, Peng
Xie, Li
Wang, Yong-Sheng
Song, Xian-Rang
author_sort Bi, Zhao
collection PubMed
description PURPOSE: The study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer. METHODS: Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT. RESULTS: Our results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. The AUC value was 0.789 (95%CI: 0.703-0.876). The multivariate logistic regression analysis identified the expression of lncRNA-AL390243.1 (OR 5.143; 95% CI: 1.570-16.847), tumor type (OR 0.144; 95% CI: 0.024-0.855), and nodal stage (OR 0.507; 95% CI: 0.289-0.888) as independent predictors for apCR after NAT in HER2+ patients (all p<0.05). Then the three predictors were used to create a predictive nomogram. The AUC value was 0.859 (95%CI: 0.790-0.929). The calibration curve showed a satisfactory fit between predictive and actual observation based on internal validation with a bootstrap resampling frequency of 1000. Patients with higher expression of lncRNA-AL390243.1 had worse survival. LncRNA-AL390243.1 was up-regulated more in the nodal positive subgroup than in the nodal negative subgroup (p=0.0271). CONCLUSION: The lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1 were upregulated in non-apCR breast cancer tissues. These three lncRNAs might have the potential to be used as predictive biomarkers of nodal efficacy of HER2+ breast cancer. Further studies are required to illuminate the underlying molecular mechanisms further.
format Online
Article
Text
id pubmed-8685269
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86852692021-12-21 A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer Bi, Zhao Qiu, Peng-Fei Zhang, Yue Song, Xing-Guo Chen, Peng Xie, Li Wang, Yong-Sheng Song, Xian-Rang Front Oncol Oncology PURPOSE: The study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer. METHODS: Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT. RESULTS: Our results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. The AUC value was 0.789 (95%CI: 0.703-0.876). The multivariate logistic regression analysis identified the expression of lncRNA-AL390243.1 (OR 5.143; 95% CI: 1.570-16.847), tumor type (OR 0.144; 95% CI: 0.024-0.855), and nodal stage (OR 0.507; 95% CI: 0.289-0.888) as independent predictors for apCR after NAT in HER2+ patients (all p<0.05). Then the three predictors were used to create a predictive nomogram. The AUC value was 0.859 (95%CI: 0.790-0.929). The calibration curve showed a satisfactory fit between predictive and actual observation based on internal validation with a bootstrap resampling frequency of 1000. Patients with higher expression of lncRNA-AL390243.1 had worse survival. LncRNA-AL390243.1 was up-regulated more in the nodal positive subgroup than in the nodal negative subgroup (p=0.0271). CONCLUSION: The lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1 were upregulated in non-apCR breast cancer tissues. These three lncRNAs might have the potential to be used as predictive biomarkers of nodal efficacy of HER2+ breast cancer. Further studies are required to illuminate the underlying molecular mechanisms further. Frontiers Media S.A. 2021-12-06 /pmc/articles/PMC8685269/ /pubmed/34938660 http://dx.doi.org/10.3389/fonc.2021.779140 Text en Copyright © 2021 Bi, Qiu, Zhang, Song, Chen, Xie, Wang and Song https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bi, Zhao
Qiu, Peng-Fei
Zhang, Yue
Song, Xing-Guo
Chen, Peng
Xie, Li
Wang, Yong-Sheng
Song, Xian-Rang
A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
title A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
title_full A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
title_fullStr A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
title_full_unstemmed A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
title_short A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
title_sort three lncrna set: ac009975.1, poteh-as1 and al390243.1 as nodal efficacy biomarker of neoadjuvant therapy for her-2 positive breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685269/
https://www.ncbi.nlm.nih.gov/pubmed/34938660
http://dx.doi.org/10.3389/fonc.2021.779140
work_keys_str_mv AT bizhao athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT qiupengfei athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT zhangyue athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT songxingguo athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT chenpeng athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT xieli athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT wangyongsheng athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT songxianrang athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT bizhao threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT qiupengfei threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT zhangyue threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT songxingguo threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT chenpeng threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT xieli threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT wangyongsheng threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer
AT songxianrang threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer